To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
ASTX660-03A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma | |
---|---|
Local Project Reference: | 149376 |
Principal Investigator: | Dr William Townsend |
Drug Class/ Treatment: | Tolinapant (non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP)) Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine alone |
Patient Population: | Peripheral T-Cell Lymphoma |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
CO43805A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB OR GLOFITAMAB IN COMBINATION WITH CC-220 AND CC-99282 IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA | |
---|---|
Local Project Reference: | 149649 |
Principal Investigator: | Dr WIlliam Townsend |
Drug Class/Treatment: | Mosunetuzumab (bispecific CD20-directed CD3 T-cell engager) or Glofitamab (CD20- and CD3- Bispecific Antibody) In Combination with CC-220 (cereblon E3 ligase modulator) + CC-99282 (E3 Ligase Modulator) |
Patient Population: | B-Cell Non-Hodgkin Lymphoma |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
ALLCAR19Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19) | |
---|---|
Local Project Reference: | 16/0530 |
Principal Investigator: | Dr Claire Roddie |
Drug Class/ Treatrment: | CAR T-Cell Therapy Expressing CD19 Chimeric Antigen Receptor (CD19CAR) |
Patient Population: |
Adults >/=16 years old |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
NAVAL-1An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) | |
---|---|
Local Project Reference: | 140945 |
Principal Investigator: | Dr. Kirit Ardeshna |
Drug Class/ Treatrment: | Nanatinostat (Histone Deacetylase Inhibitor) + Valganciclovir (Antiviral Medication) |
Patient Population: | Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
PRiZM+PRiZM+: A phase II platform study of zanubrutinib monotherapy and combination therapy for relapsed and refractory primary CNS lymphoma | |
---|---|
Local Project Reference: | 144707 |
Principal Investigator: | Dr. Kate Cwynarski |
Drug Class/ Treatrment: | Zanubrutinib (Bruton Tyrosine Kinase Inhibitor) Monotherapy and Combination Therapy |
Patient Population: | Relapsed and Refractory Primary CNS Lymphoma |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
AUTO4-TL1Phase I/II study - AUTO4 in patients with T cell non-Hodgkin Lymphoma : A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T Cell Treatment Targeting TRBC1, in Patients with Relapsed or Refractory TRBC1 positive selected T Cell Non-Hodgkin Lymphoma. | |
---|---|
Local Project Reference: | 17/0680 |
Principal Investigator: | Dr. Kate Cwynarski |
Drug Class/ Treatrment: | AUTO4 - CAR T-Cell Therapy Targeting TRBC1 |
Patient Population: | Relapsed or Refractory TRBC1 positive selected T Cell Non-Hodgkin Lymphoma. |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |